AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEUREN PHARMACEUTICALS LTD

13.010

+0.2101.64%

Volume:261.44K

Turnover:3.39M

Market Cap:1.65B

PE:11.34

High:13.100

Open:12.950

Low:12.810

Close:12.800

52wk High:22.985

52wk Low:8.610

Shares:126.64M

Float Shares:108.39M

Volume Ratio:0.70

T/O Rate:0.24%

Dividend:- -

Dividend Rate:- -

EPS(TTM):1.148

EPS(LYR):1.086

ROE:54.96%

ROA:41.13%

PB:5.10

PE(LYR):11.98

Loading ...

Overview Company News Filings

Company Profile

Company Name:

NEUREN PHARMACEUTICALS LTD

Exchange:

ASX

Establishment Date:

2001

Employees:

8

Office Location:

117 Camberwell Road,Suite 1.01,Hawthorn East,Victoria,Australia

Website:

http://www.neurenpharma.com

Zip Code:

3123

Phone:

Fax:

- -

Introduction:

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as is in Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591 that is in preclinical development for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Camberwell, Australia.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NEU.AU/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"NEU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":13.01,"timestamp":1771391520000,"preClose":12.8,"halted":0,"volume":261444,"delay":0,"changeRate":0.016406249999999928,"nameEN":"NEUREN PHARMACEUTICALS LTD","floatShares":108394581,"shares":126639526,"eps":1.147709,"marketStatus":"Closed","change":0.21,"latestTime":"02-18 16:12:00 AEDT","open":12.95,"high":13.1,"low":12.81,"amount":3388006,"amplitude":0.022656,"askPrice":13.08,"askSize":2100,"bidPrice":12.85,"bidSize":77,"shortable":3,"etf":0,"ttmEps":1.147709,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1771455600000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":12.8,"openAndCloseTimeList":[[1771369200000,1771390800000]],"volumeRatio":0.6957,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":108394581,"roa":"41.13%","roe":"54.96%","lyrEps":1.086099,"volumeRatio":0.6957,"shares":126639526,"dividePrice":0,"high":13.1,"amplitude":0.022656,"preClose":12.8,"low":12.81,"week52Low":8.61,"pbRate":"5.10","psRate":"7.53","week52High":22.985,"institutionHeld":0,"latestPrice":13.01,"committee":-0.92926,"eps":1.147709,"divideRate":0,"volume":261444,"delay":0,"ttmEps":1.147709,"open":12.95,"prevYearClose":18.61,"prevWeekClose":12.75,"prevMonthClose":16.69,"prevQuarterClose":18.61,"fiveDayClose":13.43,"twentyDayClose":18.05,"sixtyDayClose":18.49},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[],"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":20376907,"yearFounded":2001,"employeeNum":8,"address":"117 Camberwell Road,Suite 1.01,Hawthorn East,Victoria,Australia","zipCode":"3123","officePhone":"61 3 9092 0480"},"stockCompanyDetail":{"websiteUrl":"http://www.neurenpharma.com","stockEarnings":[{"period":"1week","weight":-0.0526},{"period":"1month","weight":-0.3312},{"period":"3month","weight":-0.2998},{"period":"6month","weight":-0.2614},{"period":"1year","weight":-0.0376},{"period":"ytd","weight":-0.3122}],"compareEarnings":[{"period":"1week","weight":0.0013},{"period":"1month","weight":-0.015},{"period":"3month","weight":0.0447},{"period":"6month","weight":0.0404},{"period":"1year","weight":0.2039},{"period":"ytd","weight":0.0088}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as is in Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591 that is in preclinical development for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Camberwell, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.062739},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.046478},{"month":3,"riseRate":0.47619,"avgChangeRate":0.356036},{"month":4,"riseRate":0.428571,"avgChangeRate":0.02071},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.04108},{"month":6,"riseRate":0.666667,"avgChangeRate":0.107096},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.047079},{"month":8,"riseRate":0.428571,"avgChangeRate":0.013034},{"month":9,"riseRate":0.619048,"avgChangeRate":0.114557},{"month":10,"riseRate":0.619048,"avgChangeRate":0.072663},{"month":11,"riseRate":0.47619,"avgChangeRate":0.032447},{"month":12,"riseRate":0.333333,"avgChangeRate":0.026009}],"exchange":"ASX","name":"NEUREN PHARMACEUTICALS LTD","nameEN":"NEUREN PHARMACEUTICALS LTD"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":null}}